University of Oxford

October 23, 2014

Chan Soon-Shiong Institute for Molecular Medicine and the University of Oxford Establish Partnership to Create the First Center for Genomic and Proteomic Medicine in the United Kingdom to Benefit NHS Cancer Patients as Part of a $50M Commitment

The Chan-Soon-Shiong Oxford Center for Molecular Medicine Will Advance Cancer Care with Individualized Information at the Molecular Level and State-of-the-Art Proteomic Technology

This partnership will evaluate and provide comprehensive molecular diagnostics from genomics to proteomics integrated with clinical data for cancer patients with the aim to identify the right treatment for the right patient at the right time.
— Anna Schuh, University of Oxford

The Chan Soon-Shiong Institute for Molecular Medicine (CSSIOMM) and the University of Oxford announced a partnership to establish the Chan Soon-Shiong Oxford Center for Molecular Medicine (CSSOCMM), the first of its kind in the United Kingdom designed to support the delivery of individualized, data-driven molecular based medicine for the benefit of NHS cancer patients. The Chan Soon-Shiong Institute has made an initial commitment of $50M to advance clinical cancer care in the UK through genomic and proteomic driven diagnoses. These funds will provide doctors with large-scale sequencing capabilities for patient-level genomic, epigenomic, proteomic, and digital pathology data capture as well as novel tools and supercomputing technology to support critical decision making for cancer treatment. 

Today’s announcement is being made at a press conference in London at which the Minister for Life Sciences, George Freeman MP will preside. Commenting on the announcement, he said: “This investment is a sign that Britain is leading the world in the exciting new field of Genomic Medicine. Breakthroughs in our understanding of how genetics determines how disease really works in patients is crucial to generating new treatments and medicines.

October 23, 2014 - Introduction

October 23, 2014 - Academia Discussion

October 23, 2014 - Pharma Discussion


Breakthroughs in Medicine & Technology Summit, Jackson Hole, WY

August 2015

Convening CEOs of Multinational Pharmaceutical and Insurance Companies to Increase Access to Novel Agents and Payment Models

A select group of world leaders was convened by Dr. Soon-Shiong and co-sponsored by Walgreens CEO Stefano Pessina to gather for three days in a private summit to discuss the challenges facing healthcare and the looming crisis of cancer and cognitive overload.

Participants at this three day summit included:

  1. Honorable William Clinton
  2. John Brennan (Director of the Central Intelligence Agency)
  3. Senator Bill Frist (Co-Chair of Bi Partisan Center)
  4. Governor Matt Mead (Wyoming)
  5. Bob Bradway (CEO of Amgen)
  6. Bob Hugin (CEO of Celgene)
  7. Andrew Witty (CEO of GlaxoSmithKline)
  8. Dan Hilferty (CEO of Independence Blue Cross)
  9. Joe Swedish (CEO of Anthem)
  10. Jim Huffman (SVP Bank of America)
  11. Steve Forbes (Chairman & Editor in Chief)
  12. John Chen (CEO of Blackberry)
  13. Simon Stevens (CEO of NHS England)
  14. Kathryn Davies (Executive Director, NHS Wales)
  15. Stefano Pessina (CEO of Walgreens)
  16. Arnaud Bernaert (Sr. Director, World Economic Forum)
  17. Sanjay Gupta (CNN)
  18. Christopher Penrose (SVP, AT&T)
  19. Patrick Soon-Shiong (CEO, NantWorks)
  20. Major Academic Cancer Center Directors & Community Oncologists

Cancer MoonShot 2020

January 2016

Historic National Coalition Formed to Accelerate Next Generation Immunotherapy in Cancer

Large Pharma, Biotech, Major Payer, Fortune 50 Company, Academia and Community Oncologists Join Forces to Announce Launch of Cancer MoonShot 2020 Program

  • Nation’s first insurance coverage of next generation whole genome sequencing and proteomic diagnostic platform in cancer patients

  • Next generation sequencing and precision medicine evolving from research to the clinical trial and cancer care setting

  • Coalition to design, initiate and complete randomized clinical trials at all stages of cancer in up to 20 tumor types in as many as 20,000 patients in multiple phase 1 to 3 trials by year 2020

  • Beneficiaries and patients will undergo next-generation molecular sequencing and gain access to over 60 novel and approved molecules to be tested as immunotherapy combinations in 20,000 cancer patients with cancer across all tumor types: The QUILT Program

For the full report, click here.

Watch a replay of our January 12 press event held in the San Francisco with leaders from pharma, biotech, and academic centers with the announcement of our Cancer MoonShot 2020.

Announced on January 12, 2016 - Cancer MoonShot 2020 was announced with large pharma, biotech, major payer, fortune 50 companies, academia, and community oncologists to end cancer as we know it.